BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Merck Serono Fertility Treatment Pergoveris® Receives Marketing Approval in Russia


3/16/2012 7:50:47 AM

GENEVA, March 15, 2012 /PRNewswire/ --

- Pergoveris(R)approved for the treatment of women suffering from severe deficiencyin reproductive hormones preventing them from naturally ovulating, and for women undergoing assisted reproductive technologies who do not respond well to standard treatment - Pergoveris(R) to be launched in Russia in the second quarter of 2012

Merck Serono, a division of Merck, Darmstadt, Germany, today announced that the Ministry of Health and Social Development of the Russian Federation has granted marketing authorization for Pergoveris(R) (recombinant human follitropin alfa and recombinant human lutropin alfa). Pergoveris(R) is indicated for the stimulation of follicular development in women with severe luteinizing hormone (LH) and follicle-stimulating hormone (FSH) deficiency, and for controlled ovarian stimulation in sub-optimal responders in assisted reproductive technologies (ART), who have previously had a sub-optimal response to controlled ovarian stimulation characterized by at least one of the following: small number (<7) of pre-ovulatory follicles, use of high FSH doses (greater than or equal to 3000 IU per cycle) or advanced (greater than or equal to 35 years) maternal age.

"The approval of Pergoveris(R) in Russia is part of our commitment to bring our biotechnological drugs to patients worldwide," said Belén Garijo, Head of Global Operations at Merck Serono. "Complementing the portfolio of fertility drugs already available in Russia, Pergoveris(R), with its unique formulation of recombinant LH and FSH, represents an additional treatment option for Russian women suffering from hormonal deficiencies or those who do not respond to current treatments, preventing them from getting pregnant", she added.

Pergoveris(R) is the only biotechnology medicine combining recombinant FSH 150IU and recombinant human LH 75IU that allows administration of both substances in a single subcutaneous injection. LH and FSH are hormones that are normally produced by the pituitary gland and play an important role in the female reproductive system. In the absence of endogenous FSH and LH, production and full development of follicles in the ovaries, ovulation and endometrial growth to support implantation of a fertilized egg are unlikely to occur.

While severe LH and FSH deficiency is a rare disorder of the reproductive function caused by an endocrine deficiency, sub-optimal or low ovarian response has been showed to be a first sign of ovarian ageing.[1] In patients undergoing In Vitro Fertilization (IVF) treatment, the prevalence of low ovarian response ranges from 9 to 24%.[2] Sub-optimal response can be observed following a first cycle of standard controlled ovarian stimulation, when there are insufficient mature follicles to proceed to oocyte retrieval.Often, patients undergoing IVF are of advanced maternal age (greater than or equal to 35 years).[3]

Infertility is defined by the World Health Organization as the inability for a couple to achieve conception or bring a pregnancy to term after a year or more of regular, unprotected sexual intercourse. Today it is estimated that 9% of couples worldwide experience difficulties to conceive a child, representing potentially 72 million couples.[4] Since the birth of the first IVF baby in 1978, it is estimated that over 3.75 million babies have been born worldwide thanks to ART.

In Russia, awareness of infertility and treatment options is one of the lowest worldwide,[5] but the demand to treat infertility is rising rapidly.[6] Besides having a complete portfolio of medicinal products to help treat the various causes of infertility, Merck Serono is committed to providing support to advance the management of infertility in Russia, through educational initiatives, research grants, information websites, and the introduction of additional therapies, and improved devices to facilitate self-injection of treatments by patients.



Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->